Elles M. Kemper

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Safety and Effectiveness of Pharmacy Compounded Chenodeoxycholic Acid Capsules for Patients With Cerebrotendinous Xanthomatosis.

Safety and Effectiveness of Pharmacy Compounded Chenodeoxycholic Acid Capsules for Patients With Cerebrotendinous Xanthomatosis.

Journal: Journal of inherited metabolic disease

Published: December 24, 2025

Limited sample stability of chenodeoxycholic acid in pharmaceutical quality control.

Limited sample stability of chenodeoxycholic acid in pharmaceutical quality control.

Journal: European journal of hospital pharmacy : science and practice

Published: November 05, 2025

Effect of curcumin on the gut microbiota of patients with ulcerative colitis, Crohn's disease and healthy participants.

Effect of curcumin on the gut microbiota of patients with ulcerative colitis, Crohn's disease and healthy participants.

Journal: Scientific reports

Published: September 27, 2025

Pharmacokinetic Cross-Over Study of Pharmacy-Compounded Chenodeoxycholic Acid Capsules Compared to Authorized Capsules.

Pharmacokinetic Cross-Over Study of Pharmacy-Compounded Chenodeoxycholic Acid Capsules Compared to Authorized Capsules.

Journal: Pharmaceutics

Published: September 12, 2025

Extemporaneous Compounding, Pharmacy Preparations and Related Product Care in the Netherlands.

Extemporaneous Compounding, Pharmacy Preparations and Related Product Care in the Netherlands.

Journal: Pharmaceutics

Published: June 25, 2025

Real-world population pharmacokinetics of tezacaftor-ivacaftor in children with cystic fibrosis: The SYM-CF study.

Real-world population pharmacokinetics of tezacaftor-ivacaftor in children with cystic fibrosis: The SYM-CF study.

Journal: British journal of clinical pharmacology

Published: January 13, 2025

Effectiveness and Safety of Personalized Cholic Acid Treatment in Patients With Bile Acid Synthesis Defects.

Effectiveness and Safety of Personalized Cholic Acid Treatment in Patients With Bile Acid Synthesis Defects.

Journal: Journal of inherited metabolic disease

Published: January 10, 2025

Quality assessment of cholic acid as an active pharmaceutical ingredient: Analytical method and results.

Quality assessment of cholic acid as an active pharmaceutical ingredient: Analytical method and results.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: December 27, 2024

Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study.

Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: October 16, 2024

Challenges in the identification and quantification of an unknown impurity in chenodeoxycholic acid drug substance.

Challenges in the identification and quantification of an unknown impurity in chenodeoxycholic acid drug substance.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: October 02, 2024

A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability.

A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability.

Journal: iScience

Published: August 26, 2024

The clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review.

The clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review.

Journal: Orphanet journal of rare diseases

Published: May 08, 2024

Showing 1-12 of 66

Last Updated: 09/26/2026